Overall, the low-grade group had significantly higher PTEN and PLZF scores than the moderate-grade and the high-grade subgroups (Figure 1B/C), suggesting that PLZF may also play a role in the clinical progress of prostate cancer like PTEN. This evidence concerns the gene PTEN and prostate carcinoma.